News coverage about Sorrento Therapeutics (NASDAQ:SRNE) has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sorrento Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.4870153877463 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Technical indicators to predict the future price movements of Sorrento Therapeutics, Inc. (SRNE) – Wall Street Morning (wallstreetmorning.com)
- An Ear To The Pharma: 6 Stocks To Watch This Week (markets.businessinsider.com)
- Lookout for these Two stocks: Sorrento Therapeutics, Inc. (NASDAQ:SRNE), Sabra Health Care REIT, Inc. (NASDAQ … – The Oracle Examiner (oracleexaminer.com)
- Attention Seeking Stock: Sorrento Therapeutics, Inc. (NASDAQ: SRNE) – The Investor Guide (wallstreetnews24.com)
- Sorrento Therapeutics, Inc. (SRNE) Stock with Decreasing EPS Growth For Next Year – Wallstreet Investorplace (wallstreetinvestorplace.com)
SRNE has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Sorrento Therapeutics in a research report on Thursday, February 1st. Oppenheimer reaffirmed a “buy” rating and set a $9.00 price target on shares of Sorrento Therapeutics in a research report on Friday, January 19th. BidaskClub raised shares of Sorrento Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, January 6th. Finally, ValuEngine raised shares of Sorrento Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $14.50.
In other news, major shareholder Abg Management Ltd sold 70,721 shares of the stock in a transaction on Monday, February 5th. The shares were sold at an average price of $8.00, for a total value of $565,768.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Pacific Medtech (Bvi) Ltd Asia sold 684,288 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $7.56, for a total transaction of $5,173,217.28. The disclosure for this sale can be found here. Insiders sold 1,215,009 shares of company stock valued at $9,185,885 in the last three months. Company insiders own 5.00% of the company’s stock.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.